Scientists Zero In on the Brain Network at the Root of the Disease
For decades, Parkinson’s disease has been one of neurology’s most stubborn puzzles. Now, researchers may have found a crucial missing piece.
A new study published in Nature, led by China’s Changping Laboratory in collaboration with Washington University School of Medicine in St. Louis, has identified the specific brain network responsible for Parkinson’s core symptoms — and the findings could reshape how the disease is treated.
The culprit, researchers say, is a network called the somato-cognitive action network, or SCAN. First described in Nature in 2023, SCAN sits within the motor cortex and is responsible for turning action plans into movements, as well as receiving feedback on how executing those plans went. In people with Parkinson’s, SCAN becomes abnormally overconnected to the subcortex — the brain region governing emotion, memory, and motor control. This disruption doesn’t just impair movement; it also affects cognition, digestion, sleep, and motivation, helping explain why Parkinson’s symptoms are so wide-ranging.
The researchers analyzed brain imaging data from more than 800 participants across multiple institutions in the US and China, including patients on various treatments, healthy individuals, and people with other movement disorders. The pattern was clear: all four therapies studied were most effective when they reduced hyperconnectivity between SCAN and the subcortex, normalizing activity in the circuit responsible for planning and coordinating action.
Armed with this insight, the team developed a precision treatment approach using transcranial magnetic stimulation (TMS) — a noninvasive technique that sends magnetic pulses to the brain from a device worn on the head. The results were striking: patients receiving SCAN-targeted TMS showed a 56% response rate after two weeks, compared to 22% in patients receiving stimulation at adjacent brain areas — a 2.5-fold increase in efficacy.
The implications go beyond symptom management. Because TMS doesn’t require surgery, treatment with neuromodulation could potentially begin much earlier than is currently done with deep brain stimulation, the invasive standard of care today. Researchers are also exploring whether targeting SCAN could slow or even reverse disease progression, not just mask its effects.
Parkinson’s affects over 10 million people worldwide. This discovery won’t cure it overnight — but pinpointing the network at its core is a genuine turning point, opening the door to a new era of precise, noninvasive, and potentially earlier intervention.
This topic was featured in Great News podcast episode 34.
Source: Futurity
